BIOPHARMA CREDIT PLC

Pre-Annual General Meeting Information • May 29, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5775P

BioPharma Credit PLC

29 May 2018

29 MAY 2018

BioPharma Credit plc

(the "Company")

NOTICE OF ANNUAL GENERAL MEETING

INCLUDING A RECOMMENDED PROPOSAL

FOR THE APPROVAL OF A RELATED PARTY TRANSACTION

Following the publication on 7 March 2018 of its Annual Financial Report for the year ended 31 December 2017, the Company announces that it will hold its Annual General Meeting ("AGM") at 11 a.m. on 29 June 2018 at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG.

Alongside the ordinary business to be considered at the AGM and as disclosed in the prospectus related to the Company's C Share issue dated 14 March 2018, the Company is seeking shareholders' approval of a related party transaction in respect of the amendment to the Investment Management Agreement.

A copy of the Notice of the AGM is available to view on the Company's website at http://www.bpcruk.com. It has also been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/NSM.

Copies of the Notice of the AGM, together with a form of proxy for use in connection with the AGM, are being posted or made available to the Company's Shareholders today.

Capitalised terms used in this announcement and not otherwise defined will have the meanings given to them in the Notice of AGM.

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509

Buchanan

+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27th March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOASEUFLUFASEDI